SINGAPORE — November 5, 2026
Singapore is expanding its preventive healthcare support with subsidised genetic testing for people at risk of hereditary breast and ovarian cancer (HBOC), beginning December 1, 2026.
The Ministry of Health (MOH) announced that eligible Singapore citizens and permanent residents will receive means-tested subsidies of up to 70 per cent for the tests. The remaining costs can also be offset using MediSave, with some individuals potentially paying nothing out of pocket if they have sufficient MediSave balances.
Around 2,000 people are expected to benefit annually, including patients who meet the clinical criteria and relatives who may carry the same inherited gene variants.
The programme will initially be available at three public healthcare institutions: the National Cancer Centre Singapore (NCCS), the National University Cancer Institute Singapore (NCIS) and Tan Tock Seng Hospital (TTSH).
But the announcement goes beyond making genetic tests more affordable. Singapore is also expanding financial support for selected preventive interventions, including risk-reducing surgeries and intensified medical surveillance for people found to carry relevant gene variants.
The move represents another step in the country’s shift towards preventive and personalised healthcare — identifying inherited cancer risks early enough for patients and their doctors to consider appropriate measures.
What Is Hereditary Breast and Ovarian Cancer?
Hereditary breast and ovarian cancer is associated with inherited genetic variants that can substantially increase a person’s likelihood of developing certain cancers.
Some of the best-known genes linked to HBOC are BRCA1 and BRCA2. Harmful variants in these genes can increase the risk of breast and ovarian cancer, among other cancers.
Unlike most cancer cases that are not caused by inherited mutations, HBOC-associated variants can be passed from a parent to a child.
This means that a person may carry an inherited variant even if they have never been diagnosed with cancer.
MOH estimates that approximately one in every 150 people in Singapore carries a mutation associated with HBOC.
The ministry has also highlighted the difference in lifetime cancer risks between women who carry these variants and women in the general population.
For women with HBOC-associated gene variants, the lifetime risk can reach:
- Breast cancer: Up to approximately 60 per cent, compared with up to 13 per cent in the general female population.
- Ovarian cancer: Up to approximately 50 per cent, compared with up to 2 per cent in the general female population.
These figures describe potential risks among people with relevant inherited variants. They do not mean that every carrier will develop cancer.
Genetic testing helps identify people who may benefit from closer monitoring, medical advice and appropriate preventive interventions.
Who Can Qualify for Subsidised Genetic Testing?
The new programme is intended for people whose medical or family histories indicate a higher likelihood of carrying HBOC-associated gene variants.
MOH has identified three main groups recommended for testing.
1. People diagnosed with breast or ovarian cancer who have relevant risk factors
Patients who already have breast and/or ovarian cancer may be recommended for genetic testing if their medical history or other risk factors suggest a hereditary cause.
Identifying an inherited variant can help doctors consider appropriate treatment and follow-up options. It may also provide important information for the patient’s relatives.
2. First-degree relatives of people who carry an HBOC-associated gene variant
Parents, siblings and children of someone identified as carrying a relevant inherited variant may be recommended for testing.
This is particularly important because close biological relatives may have inherited the same variant.
3. People with a strong family history of HBOC-related cancers
Individuals with a strong family history suggestive of hereditary breast and ovarian cancer may also qualify, even when they do not have an affected first-degree relative available for testing.
A doctor will need to assess the family history and determine whether genetic testing is clinically appropriate.
Meeting one of these broad descriptions does not automatically guarantee eligibility. Testing and subsidies must follow the relevant clinical criteria and approved referral pathways.
Which Hospitals Will Offer the Tests?
From December 1, subsidised HBOC genetic testing will be offered at cancer specialist outpatient clinics at three institutions:
- National Cancer Centre Singapore
- National University Cancer Institute Singapore
- Tan Tock Seng Hospital
Individuals who are unsure whether they or their relatives should undergo testing are encouraged to consult their doctors.
Medical professionals can assess personal and family histories, determine whether the clinical criteria are met and arrange an appropriate referral.
The programme is not intended to encourage everyone to undergo genetic testing without medical assessment. Its focus is on identifying individuals with relevant risk factors who are likely to benefit from the results.
How Much Will the Genetic Test Cost?
The new financing arrangement could significantly reduce the financial burden for eligible patients.
Singapore citizens and permanent residents who meet the clinical requirements can receive means-tested subsidies of up to 70 per cent.
Additional subsidies are available for eligible seniors from the Pioneer Generation and Merdeka Generation.
After the government subsidy, the remaining amount can be paid using MediSave under the applicable financing arrangements.
MOH provided indicative figures showing how the support could work:
| Type of genetic testing | Approximate cost before subsidies | Potential cost after subsidies and MediSave |
|---|---|---|
| Initial patient testing | S$1,000 | S$0 |
| Testing of an identified relative | S$550 | S$0 |
The S$0 figures apply to individuals with sufficient MediSave balances to cover the remaining eligible amount. They should not be interpreted as a guarantee that every patient will have no out-of-pocket expense.
In the interim before the enhanced MediSave Chronic and Preventive Care scheme takes effect on January 1, 2027, existing MediSave500/700 limits will be extended to cover the genetic tests.
Seniors aged 60 and above may also use Flexi-MediSave to help pay any remaining eligible costs.
From January 2027, the enhanced MediSave scheme will provide higher annual withdrawal limits under its applicable categories.
Why Men Can Also Receive Subsidised Genetic Testing
One important detail in the announcement is that the HBOC genetic-testing subsidies apply to eligible individuals regardless of gender.
Although hereditary breast and ovarian cancer is often discussed in relation to women’s health, men can also carry HBOC-associated gene variants.
Male carriers can pass inherited variants to their children, including daughters who may face increased risks of certain cancers.
This is why testing family members is important even when the person carrying the variant is male.
The policy also recognises that hereditary cancer risk can affect an entire family rather than only the individual who first receives a diagnosis.
What Happens When Someone Tests Positive?
A positive genetic test does not mean that a person definitely has cancer or will develop it.
Instead, the result identifies an inherited genetic risk that can help doctors recommend appropriate follow-up care.
Depending on the specific gene variant, personal circumstances and clinical assessment, recommended interventions may include:
- More frequent breast screening and medical surveillance.
- Magnetic resonance imaging (MRI) or mammograms at intervals recommended by doctors.
- Certain preventive medications, where clinically appropriate.
- Risk-reducing surgery for individuals who meet the relevant medical criteria.
The purpose is to give patients and their healthcare teams more information to make decisions about prevention and early detection.
MOH has said that genetic counselling is part of the testing pathway, helping individuals understand the implications of testing before and after receiving their results.
Family Members Can Also Benefit Through Cascade Testing
The programme includes financial support for a process known as cascade testing.
This involves offering genetic testing to close biological relatives after an individual is identified as carrying an HBOC-associated gene variant.
For example, if a patient tests positive, doctors may recommend testing the patient’s parents, siblings or children to determine whether they have inherited the same variant.
The approach can help identify relatives who may benefit from earlier surveillance or other preventive measures.
It can also help relatives who do not carry the identified family variant avoid unnecessary follow-up specifically related to that inherited risk, subject to their individual medical circumstances.
MOH has confirmed that eligible cascade testing will receive similar subsidies and MediSave support.
This is a significant part of the programme because identifying one carrier may help doctors assess inherited risks across several members of the same family.
Preventive Surgery Will Also Receive Expanded Financial Support
The new genetic-testing programme is part of a broader financing package that includes selected downstream interventions.
For some people with clinically significant HBOC-associated variants, doctors may discuss risk-reducing surgery as one possible way to lower future cancer risk.
Two procedures are covered under the expanded support framework.
Risk-reducing mastectomy
This procedure involves removing breast tissue to substantially reduce the risk of breast cancer in individuals with relevant inherited variants.
MOH says the procedure can reduce breast cancer risk by 90 per cent or more in individuals with HBOC-associated variants.
MediShield Life and MediSave coverage for eligible risk-reducing mastectomy procedures has been extended since September 28, 2026, subject to the applicable clinical criteria.
Risk-reducing bilateral salpingo-oophorectomy
This procedure involves removing both fallopian tubes and ovaries to reduce the risk of ovarian cancer.
According to MOH, it can reduce ovarian cancer risk by 80 per cent or more in individuals with relevant inherited variants.
Similar MediShield Life and MediSave coverage for eligible procedures is scheduled to be extended by the end of 2026.
These procedures are not automatic recommendations for everyone who tests positive. Decisions depend on the specific genetic findings, medical history, age, individual circumstances and discussions between patients and their doctors.
The Agency for Care Effectiveness has recommended subsidies for genetic testing and the relevant risk-reducing surgeries when performed in accordance with the established clinical criteria.
Why Singapore Is Expanding Preventive Healthcare
The announcement reflects a wider healthcare strategy that places greater emphasis on identifying risks before they develop into more serious medical problems.
MOH previously announced subsidised genetic testing for familial hypercholesterolaemia, an inherited condition associated with high cholesterol and increased cardiovascular risk.
The expansion to HBOC adds another hereditary condition to the list of genetic tests receiving mainstream financial support.
The ministry has said that clinical effectiveness and cost-effectiveness are key considerations when deciding which conditions should qualify for subsidised testing.
In Parliament on November 3, MOH reiterated that genetic testing should meaningfully inform medical management and improve health outcomes through early detection and appropriate intervention.
This means the government is not simply subsidising tests because they are technologically available. The aim is to support testing where the results can lead to clinically useful decisions and better care.
A Previous National Cancer Centre Privacy Incident Raises Another Important Issue
The expansion of hereditary cancer services also brings renewed attention to the importance of protecting sensitive health information.
In September 2026, the National Cancer Centre Singapore apologised after an administrative error exposed the email addresses of 467 recipients invited to an event connected to hereditary breast and ovarian cancer.
The centre said the email addresses were visible because recipients had been placed in the regular carbon-copy field rather than the blind-carbon-copy field.
NCCS stressed that NRIC numbers, telephone numbers and other personal data were not disclosed in the incident. It said it had notified the relevant authorities and was reviewing its internal procedures.
A separate WWC ONE MEDIA report examined the same incident and the privacy concerns surrounding the exposure of the 467 recipients’ email addresses.
The two incidents are separate: the new subsidy programme concerns access to genetic testing and preventive care, while the earlier case involved an email privacy lapse. Nevertheless, both highlight the importance of public trust when healthcare institutions handle sensitive hereditary and medical information.
Healthcare Data Security Matters as More People Access Genetic Services
As genetic testing becomes more accessible, healthcare institutions will handle increasing amounts of sensitive information about patients and their biological relatives.
Genetic results can reveal information not only about the person tested but also about potential inherited risks within a family.
That makes secure handling, appropriate access controls and clear communication particularly important.
A separate data breach involving healthcare administrator Alliance Medinet affected approximately 110,000 members and raised wider questions about the protection of personal information across Singapore’s healthcare and insurance networks.
Although that incident was unrelated to HBOC testing, it illustrates why public confidence in healthcare services depends on both access to treatment and responsible protection of personal information.
What the New Programme Means for Singaporean Families
The December 1 rollout could make hereditary cancer testing more financially accessible to people who meet the medical criteria.
For an individual with a relevant cancer diagnosis or a strong family history, testing may provide information that helps doctors recommend closer monitoring or other preventive measures.
For relatives, cascade testing could identify inherited risks that might otherwise remain unknown until a family member develops cancer.
The financial support also addresses an important barrier: the cost of testing and the follow-up care that may be recommended after a positive result.
However, the programme does not mean that everyone with a family history of cancer needs a genetic test, nor does a positive result automatically mean that preventive surgery is necessary.
Medical assessment remains central to deciding who should be tested and what should happen afterwards.
Singapore’s Next Step in the Fight Against Hereditary Cancer
The introduction of subsidised HBOC genetic testing marks a significant expansion of Singapore’s preventive healthcare framework.
From December 1, eligible Singapore citizens and permanent residents can access means-tested subsidies of up to 70 per cent, with MediSave available to help offset the remaining eligible costs.
The programme will cover testing for people with relevant risk factors and eligible relatives, while additional financing support will help with selected surveillance, medication and preventive procedures.
The estimated 2,000 beneficiaries each year represent more than a testing target. The initiative is designed to help families understand inherited cancer risks and make informed decisions with their doctors.
The bigger test will be whether improved access to genetic information translates into earlier intervention, more affordable follow-up care and better long-term health outcomes.
For families with a history of breast or ovarian cancer, the message is clear: speak with a healthcare professional about whether hereditary risk assessment is appropriate, rather than relying on family history or online information alone.
